Since fractionated RT can induce PD-1 expression in tumor infiltrating CD4+ and CD8+ T cells hours after treatment, checkpoint blockade administered at this time likely blocks the PD-1/L1 signaling axis thereby augmenting T cell responses and preventing T cell anergy (67). Here, PDCD1 is linked to neoplasm.